GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
This study has been terminated.
(Study protocol amended to a new treatment regimen: study DAVFU-006.)
Sponsor:
Galectin Therapeutics Inc.
Information provided by (Responsible Party):
Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00110721
First received: May 12, 2005
Last updated: March 5, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | February 2008 |
| Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |